uniQure NV (LTS:0EE0) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0EE0 uniQure NV LTS:0EE0
43 GF Score
Price $39.81
GF Value $6.04
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV FFO per Share?

FFO per Share only applies to REITs.

LTS:0EE0
43GF Score
uniQure NV LTS:0EE0
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is uniQure NV (LTS:0EE0) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of $39.81 is trading 559.1% above its estimated GF Value™ of $6.04. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for LTS:0EE0:

  • FFO per Share:
  • GF Value™: $6.04 vs. price of $39.81 (559.1% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
43GF Score

Get the complete analysis for LTS:0EE0

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.81
Price
$6.04
GF Value